Image Ben Hargreaves R&D Growing threat of AMR: UN calls for urgent global action In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to c R&D Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal... Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. Digital FDA decision casts doubts over future of psychedelic treatme... Psychedelic therapies have emerged as a promising frontier in mental health treatment, sparking interest from researchers and investors alike. Patients Gilead's HIV success and controversy: Expanding access amid ... Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. Load more results
R&D Growing threat of AMR: UN calls for urgent global action In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to c
R&D Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal... Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
Digital FDA decision casts doubts over future of psychedelic treatme... Psychedelic therapies have emerged as a promising frontier in mental health treatment, sparking interest from researchers and investors alike.
Patients Gilead's HIV success and controversy: Expanding access amid ... Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
